I am a medical oncologist and hematologist who is part of a close-knit team of lymphoma experts at Memorial Sloan Kettering. Together, our goal is to provide compassionate, comprehensive care that will result in the best outcomes for our patients. I have more than 11 years of experience in treating Hodgkin lymphoma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL). My research focuses on finding new, more effective treatments for people with these diseases.
I have very early memories of being interested in medicine. As a child, doctor appointments were always a source of fascination. This fascination continued into college, where I was exposed to oncology research and the advances being made in caring for people with blood cancers. I realized that I wanted to be a part of this progress and have since dedicated my career to helping people with lymphoma.
At MSK, we are making great strides in finding new ways to treat and cure lymphoma, and my research aims to continue this progress. My work in early drug development, in collaboration with labs around the world, has helped lead to FDA approval of several new drugs, including bendamustine, bortezomib, ibrutinib, and venetoclax. Currently, I am the principal investigator of clinical trials that are exploring innovative ways to combine existing drugs with newer treatments. The goal of these trials is to maximize responses while minimizing side effects in people being treated for lymphoma. Many of my patients have benefited enormously from enrolling in trials like these when standard treatments did not work. I am also a member of MSK’s Developmental Therapeutics Group, which is a team of medical oncologists dedicated to providing access to the newest phase I agents for people with all types of cancer.
When people who have been diagnosed with lymphoma come to see me, my number-one goal is to cure their disease. In cases when this may not be possible, I offer patients options to help them live with and manage their disease with minimal discomfort. Regardless of prognosis, all patients who come to MSK for their lymphoma treatment have an entire team of experts in their corner.
When I’m not working, I enjoy all aspects of fitness (healthy diet, exercise, and mindfulness), cooking, photography, and traveling.
- Clinical Expertise: Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia (CLL); Lymphoma Clinical Trials; Lymphoma and Solid Tumor Drug Development
- Awards and Honors: John Mendelsohn Medical Oncology Teaching Award (2002-2003); American Society of Hematology Champion of Advocacy Award (2006); Paul Sherlock Housestaff Teaching Award (2007-2008)
- Languages Spoken: English
- Education: MD, New York University School of Medicine
- Residencies: Internal Medicine - University of Pennsylvania
- Fellowships: Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by John F. Gerecitano
Clinical Trials Co-Investigated by John F. Gerecitano
- A Phase 1/2a Study of Ibrutinib plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
- A Phase I Study of DS-3032B in Patients with Advanced Solid Tumors or Lymphomas
- A Phase I Study of GSK2857916 in Patients with Recurrent or Persistent Multiple Myeloma
- A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
- A Phase I Study of RXDX-101 in Patients with Locally Advanced or Metastatic Cancers Containing Alternations in the TRKA, TRKB, TRKC, ROS1, or ALK Proteins
- A Phase I Study of RXDX-105 for Patients with Advanced Solid Tumors
- A Phase IB Study of BCL201 and Idelalisib in Patients with Recurrent or Persistent Follicular Lymphoma and Mantle Cell Lymphoma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more